Compare AIRE & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | CALC |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 9.3M |
| IPO Year | 2023 | 2020 |
| Metric | AIRE | CALC |
|---|---|---|
| Price | $0.25 | $0.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.25 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.4M | 283.5K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $168.41 | N/A |
| Revenue Next Year | $79.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.14 | $0.46 |
| 52 Week High | $1.55 | $7.20 |
| Indicator | AIRE | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 34.86 |
| Support Level | $0.14 | $0.49 |
| Resistance Level | $0.35 | $0.79 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 23.86 | 16.43 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.